Rexgenero receives Scientific Advice letter from the Paul Ehlich Institute (PEI)


Rexgenero receives scientific advice from the Paul Ehlich Institute (the German pharmaceutical regulator) regarding quality and clinical aspects of Rexgenero planned phase III study with REX-001 in critical limb ischemia following a meeting with PEI on 8th September 2015. The PEI confirmed that the proposed multi-centre, randomized placebo-controlled design as well as the dose and primary endpoint is acceptable.

innovative cell therapies
Contact us